Asset manager 65 Equity Partners is backing Swiss pharmaceutical ingredient maker Healthcare Advanced Synthesis SA’s ...

The pharma will acquire Araris Biotech to gain access to three preclinical ADCs and a linking technology Araris claims is ...

The acquisition is supported by 65 Equity Partners, a global investment firm dedicated to supporting family-owned businesses, founders, and entrepreneurs. As part of the transaction, 65 Equity ...

Switzerland and the EU have just concluded a new package of bilateral agreements. Here are some key figures on the ...

LONDON] Asset manager 65 Equity Partners is backing Swiss pharmaceutical ingredient maker Healthcare Advanced Synthesis’ (HAS ...

Otsuka’s Taiho Pharmaceutical is paying $400 million upfront to acquire Switzerland’s Araris Biotech and its antibody-drug conjugate (ADC) linker platform.

Swiss National Bank raised its position in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE – Free Report) by 2.5% in the 4th quarter, Holdings Channel reports.The firm owned 163,152 shares of the ...

Taiho Pharmaceutical has agreed to acquire Swiss-based antibody-drug-conjugate (ADC) specialist Araris Biotech for up to ...

For some Big Pharma companies, sales in China contributed to more than 10 percent of global sales, making China a top market ...

The bench said that public good outweighs the company’s profit as the drug is not available at an affordable price in India.

AstraZeneca has tapped Korea's Alteogen to develop subcutaneous cancer drugs. Taiho Pharmaceutical is paying $400 million to ...

In 2023, the Swiss Biotech Association reported that the life sciences sector—pharmaceuticals, vitamins and diagnostics—became the country’s largest export industry. Swiss biotech revenues ...